Biotech Values

[DewDiligence]

Judge Denies Teva’s Motion to Dismiss Charge of Inequitable Conduct in Copaxone Patent Case

[The Court scheduled a separate mini-trial starting 7/11/11 on MYL’s inequitable-conduct argument against Teva; the ruling in this mini-trial will presumably dictate whether NVS/MNTA can prevail against Teva on the inequitable-conduct argument, which is one of four arguments NVS/MNTA and MYL are pursuing in the Copaxone patent case (#msg-56147443). The main trial for the arguments other than inequitable conduct will begin on 9/7/11, as previously announced.]

http://finance.yahoo.com/news/Mylan-Defeats-Tevas-Motion-prnews-486671847.html?x=0&.v=1

›Friday June 17, 2011, 4:18 pm EDT

PITTSBURGH, June 17, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq:MYL) today confirmed that the U.S. District Court for the Southern District of New York has denied Teva's motion for a summary judgment finding of no inequitable conduct in relation to Copaxone®.

In addition, the court set a start date of July 11, 2011, for the trial regarding Mylan's inequitable conduct affirmative defense. The remaining issues will be tried beginning on Sept. 7, 2011.‹